Skip to main content
News > News > Cancer-fighting viruses win U.S.A. FDA approval

Cancer-fighting viruses win U.S.A. FDA approval

On 27 October 2015, the US Food and Drug Administration (FDA) approved Amgen®’s genetically engineered virus called talimogene laherparepvec (T-VEC), brand named IMLYGIC™, to treat melanoma skin cancer.

Engineered oncolytic herpesvirus’ (oHSV) kill cancer cells by infecting the cancer cells, reproducing, and exploding from the cancer cell, thereby killing the cancer cell.  In essence, the therapy creates a cold-sore in the cancer.

As an immunotherapy, this oncolytic virus provokes an immune response against melanoma cancer.  It is the first treatment of its kind to be approved for use in the United States.  This now provides a pathway for an entire new class of therapies.

http://www.nature.com/news/cancer-fighting-viruses-win-approval-1.18651?WT.mc_id=TWT_NatureNews

We Believe

Open Therapeutics crowdsources orphan and dormant therapeutic intellectual properties (IP) to scientists around the world. The goal is advancing research that ordinarily has not generated a public value or been recognized. This approach particularly helps underserved scientists to collaborate with their more financially capable colleagues.

How open science helps researchers succeed:

Open access, open data, open source, and other open scholarship practices are growing in popularity and necessity. However, widespread adoption of these practices has not yet been achieved. One reason is that researchers are uncertain about how sharing their work will affect their careers.

The review of the literature demonstrates that open science is associated with increases in citations, media attention, potential collaborators, job opportunities, and funding opportunities. These findings are evidence that open science practices bring significant benefits to researchers relative to more traditional closed practices.

Secured By miniOrange